According to filings with the U.S. Securities and Exchange Commission, ImmunoVec is raising up to $14,999,944.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About ImmunoVec
ImmunoVec is a biotechnology company developing in vivo cell engineering therapies designed to precisely reprogram targeted cell types within the human body. It focuses on creating treatments for autoimmune diseases, solid tumors, and genetic disorders, using a pipeline of cell typespecific therapies built across both viral and non-viral delivery vehicles. Central to ImmunoVecs approach are proprietary synthetic, cell type-specific expression cassettes/promoters that can be incorporated into any delivery vehicle to drive precise and durable expression of therapeutic payloads only in intended cells, even if off-target delivery occurs. The company is pioneering programmable medicine by enabling highly precise engineering of diverse cell types and is advancing novel non-viral polymeric nanoparticles for in vivo immune cell engineering as part of its preclinical pipeline. ImmunoVec operates out of the California NanoSystems Institute (CNSI) in Los Angeles, giving it access to world-class facilities and collaborations, and is led by scientific co-founders Ryan Wong, Ph.D., and Luke Riggan, Ph.D., alongside experienced industry and venture leaders.

To learn more, visit https://www.immunovec.com/
LinkedIn: https://www.linkedin.com/company/immunovec

Contact:
Ryan Wong, Chief Executive Officer

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.